Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

Samir D. Undevia, Nicholas J. Vogelzang, Ann M. Mauer, Linda Janisch, Sridhar Mani, Mark J. Ratain

Research output: Contribution to journalArticle

37 Scopus citations

Fingerprint Dive into the research topics of 'Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors'. Together they form a unique fingerprint.

Medicine & Life Sciences